TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
M&A mergers and acquisitions business deal

Edwards Lifesciences sells critical care business to BD for $4.2B—remains ‘laser focused’ on structural heart disease

This move represents a pivot of sorts for Edwards; instead of pursuing a spin-off of its critical care business, the company is now doubling down on its commitment to develop new structural heart technologies. BD, meanwhile, says the transaction will deliver significant value. 

Thumbnail

Osteosarcopenia linked to much higher risk of death after TAVR—CT screening may prove valuable

Osteosarcopenia, an age-related condition associated with deterioration in the muscles and bones, nearly triples a patient’s risk of dying within one year of undergoing TAVR. 

alternative approaches for transcatheter aortic valve replacement procedures

Transcaval TAVR a safe, effective alternative for patients with severe AS

Researchers examined data from eight different studies, noting that transcaval TAVR appears to be a "viable alternative" when transfemoral access is not an option. The procedure was linked to an overall success rate of 98.5%.

Newsweek ranked the 50 best heart hospitals in the world

New York Valves, CRF’s newest cardiology conference, makes heart team collaborations a priority

New York Valves: The Structural Heart Summit replaces the Transcatheter Valve Therapy conference CRF hosted for many years. The three-day event will include 12 late-breaking clinical trials focused on TAVR and new treatments for the mitral and tricuspid valves. 

doctor examines patient data on their tablet

AVR for moderate AS: New 10-year data highlight clear benefits of TAVR, surgery

New research out of Cleveland Clinic explored long-term outcomes among patients with moderate aortic stenosis who were treated with TAVR, SAVR or clinical surveillance. TAVR and SAVR were both associated with clear improvements compared to surveillance alone. 

The EuroPCR 2024 meeting May 14-17 in Paris included four days of late-breaking interventional cardiology science presentations featured 12,100 participants, more than 550 educational sessions and 12 live cases. Photo courtesy of EuroPCR

5 takeaways from late-breaking studies at EuroPCR

The Society for Cardiovascular Angiography and Interventions offers its top five key takeaways from the EuroPCR 2024 meeting last week.

Medicare money payment physician

Hospital to pay $24.3M over TAVR allegations

According to a whistleblower, Cape Cod Hospital performed hundreds of TAVR procedures without following specific government requirements.

Meril Life Sciences, an India-based medical device company founded in 2006, developed the Myval TAVR valve

Myval TAVR valve noninferior to similar devices from Medtronic, Edwards after 30 days

The balloon-expandable valve is already approved for use in India and Europe. New data presented at EuroPCR 2024 in Paris compared it to contemporary devices seen by many as the gold standard for TAVR care. 

Displaying 73 - 80 of 419
Design by Adaptive Theme